Provided by Tiger Trade Technology Pte. Ltd.

NEUROGENE INC

34.67
+0.98002.91%
Post-market: 34.670.00000.00%19:30 EDT
Volume:232.13K
Turnover:7.99M
Market Cap:693.80M
PE:-6.87
High:34.86
Open:34.04
Low:33.53
Close:33.69
52wk High:43.66
52wk Low:15.93
Shares:20.01M
Float Shares:11.34M
Volume Ratio:1.30
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0440
EPS(LYR):-4.2400
ROE:-45.32%
ROA:-27.97%
PB:3.20
PE(LYR):-8.18

Loading ...

Neurogene Inc Expected to Post a Loss of $1.42 a Share - Earnings Preview

Reuters
·
Aug 07

Neurogene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 05

Neurogene (NGNE) Receives a Buy from LifeSci Capital

TIPRANKS
·
Jul 11

Neurogene President, CFO Christine Mikail Cvijic Sells 4,800 Shares for $173,468.40

Reuters
·
Jul 08

Neurogene Grants Inducement Stock Options for 96,450 Shares to New Employees

Reuters
·
Jul 07

Neurogene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 07

Neurogene President, CFO Christine Mikail Cvijic Sells 4,800 Common Shares for $166,407.28

Reuters
·
Jul 03

Neurogene Says Cash Runway Extends into Q1 2029 After USD 134.8 Million Stock Offering

Reuters
·
Jul 02

U.S. Stocks on the Move-general Mills, Meta, Lockheed Martin

Reuters
·
Jul 01

Neurogene Prices USD 125 Million Follow-on Stock Offering at USD 30 Per Share

Reuters
·
Jul 01

Neurogene - Prices Public Offering of 3.5 Mln Shares at $30 Per Share

THOMSON REUTERS
·
Jul 01

Neurogene to Sell Shares in Secondary Offering

Dow Jones
·
Jul 01

Neurogene Inc: Files for Offering of Common Stock, Pre-funded Warrants to Buy Common Stock; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Jul 01

Neurogene Drops After Starting Equity Offering

Reuters
·
Jul 01

Neurogene announces common stock offering, no amount given

TIPRANKS
·
Jul 01

Neurogene Commences Public Offering of Common Stock, Pre-funded Warrants

Reuters
·
Jul 01

Neurogene Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
Jul 01

Neurogene - Proceeds to Fund Ngn-401 Development, Pre-commercial Activities, and General Corporate Purposes

THOMSON REUTERS
·
Jul 01

Guggenheim Reaffirms Their Buy Rating on Neurogene (NGNE)

TIPRANKS
·
Jun 30

Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

TIPRANKS
·
Jun 29